REGINfo: NOVARTIS - Chimie de spécialité - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$NOVARTIS: Click to view the issuer\'s details$

Last update : 28/01/2011 >View issuer details

2020.05.27 | 07:17 | Permanent Information Releases / General Company News

puce Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease - HTML (w)

2020.05.27 | 07:15 | Permanent Information Releases / General Company News

puce Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS) - HTML (w)

2020.05.19 | 07:15 | Permanent Information Releases / General Company News

puce AveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA) - HTML (w)

2020.05.14 | 15:05 | Permanent Information Releases / General Company News

puce Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms - HTML (w)

2020.05.06 | 20:29 | Permanent Information Releases / General Company News

puce Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14 - HTML (w)

2020.05.01 | 07:15 | Permanent Information Releases / General Company News

puce Novartis receives CHMP positive opinion for Enerzair® Breezhaler® (QVM149), a potential first-in-class inhaled LABA/LAMA/ICS combination for uncontrolled asthma - HTML (w)

2020.04.29 | 07:15 | Permanent Information Releases / General Company News

puce Novartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum - HTML (w)

2020.04.28 | 07:00 | Periodic information / 1st Quarter Information

puce Novartis setzt im 1. Quartal die starke operative Performance fort, bestätigt derzeit die Prognose 2020 und fördert verschiedenste Aktivitäten, um globale Massnahmen gegen COVID-19 zu unterstützen - HTML (w)

2020.04.28 | 07:00 | Periodic information / 1st Quarter Information

puce Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19 - HTML (w)

2020.04.28 | 07:00 | Periodic information / 1st Quarter Information

puce Novartis conserve une forte performance opérationnelle au 1er trimestre, confirme à ce stade les prévisions pour 2020 et fournit de grands efforts pour contribuer à la réponse mondiale au Covid-19 - HTML (w)

2020.04.22 | 23:01 | Permanent Information Releases / General Company News

puce Novartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease - HTML (w)

2020.04.22 | 07:15 | Permanent Information Releases / General Company News

puce Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma - HTML (w)

2020.04.21 | 07:15 | Permanent Information Releases / General Company News

puce Novartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS) - HTML (w)

2020.04.20 | 07:32 | Permanent Information Releases / General Company News

puce Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients - HTML (w)

2020.04.20 | 07:17 | Permanent Information Releases / General Company News

puce Novartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye” - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1314